[go: up one dir, main page]

WO2024197344A1 - Procédé de stérilisation - Google Patents

Procédé de stérilisation Download PDF

Info

Publication number
WO2024197344A1
WO2024197344A1 PCT/AU2024/050280 AU2024050280W WO2024197344A1 WO 2024197344 A1 WO2024197344 A1 WO 2024197344A1 AU 2024050280 W AU2024050280 W AU 2024050280W WO 2024197344 A1 WO2024197344 A1 WO 2024197344A1
Authority
WO
WIPO (PCT)
Prior art keywords
pallet
sealed
sealed container
carton
box
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/AU2024/050280
Other languages
English (en)
Inventor
Jennifer Hunt
Malvin EUTICK
William Glover
Alexander Eutick
Marie AZZI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phebra Pty Ltd
Original Assignee
Phebra Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2023900854A external-priority patent/AU2023900854A0/en
Application filed by Phebra Pty Ltd filed Critical Phebra Pty Ltd
Priority to AU2024254746A priority Critical patent/AU2024254746A1/en
Publication of WO2024197344A1 publication Critical patent/WO2024197344A1/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D71/00—Bundles of articles held together by packaging elements for convenience of storage or transport, e.g. portable segregating carrier for plural receptacles such as beer cans or pop bottles; Bales of material
    • B65D71/0088—Palletisable loads, i.e. loads intended to be transported by means of a fork-lift truck
    • B65D71/0092—Palletisable loads, i.e. loads intended to be transported by means of a fork-lift truck provided with one or more rigid supports, at least one dimension of the supports corresponding to a dimension of the load, e.g. skids
    • B65D71/0096—Palletisable loads, i.e. loads intended to be transported by means of a fork-lift truck provided with one or more rigid supports, at least one dimension of the supports corresponding to a dimension of the load, e.g. skids the dimensions of the supports corresponding to the periphery of the load, e.g. pallets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
    • A61L2/04—Heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A61L2/20—Gaseous substances, e.g. vapours
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A61L2/20—Gaseous substances, e.g. vapours
    • A61L2/206—Ethylene oxide
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D85/00—Containers, packaging elements or packages, specially adapted for particular articles or materials
    • B65D85/70—Containers, packaging elements or packages, specially adapted for particular articles or materials for materials not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
    • A61L2202/20—Targets to be treated
    • A61L2202/23—Containers, e.g. vials, bottles, syringes, mail
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D19/00—Pallets or like platforms, with or without side walls, for supporting loads to be lifted or lowered
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D77/00—Packages formed by enclosing articles or materials in preformed containers, e.g. boxes, cartons, sacks or bags
    • B65D77/04—Articles or materials enclosed in two or more containers disposed one within another
    • B65D77/0413—Articles or materials enclosed in two or more containers disposed one within another the inner and outer containers being rigid or semi-rigid and the outer container being of polygonal cross-section formed by folding or erecting one or more blanks, e.g. carton

Definitions

  • the present invention relates to a method of sterilizing the exterior surface of at least one sealed container, in which the at least one sealed container comprises a pharmaceutical in fluid form.
  • the present invention also relates to at least one sealed container sterilized by the method.
  • standard manufacturing methods include use of nitrogen or inert gas sparging and overlay and/or terminal or aseptic fill.
  • Another suitable method may include the addition of chemicals to inhibit or react with residual oxygen, and these chemicals may include sodium metabisulphite, ethylenediaminetetraacetic acid (EDTA) or butylated hydroxytoluene (BHT) as examples.
  • EDTA ethylenediaminetetraacetic acid
  • BHT butylated hydroxytoluene
  • the container is exteriorly sterilised with alcohol or similar sterilant prior to entering the theatre or (ii) the entire container is held in an extra outer container or packaging of which the content is pre- sterilised (commonly known as a “theatre pack”).
  • theatre pack commonly known as a “theatre pack”.
  • the latter is the preferred option, as the simple and usually smooth outer pack shell can be sterilised prior to entry and when needed the vial or ampoule can be held in the operating theatre and the drug extracted or decanted directly into or onto a sterile field for rapid use without further sterilization. This facilitates a greater degree of control of contamination and allows a faster use of the contained pharmaceutical for the clinician and patient.
  • ampoules have been used in these situations and as they have a continuous and smooth surface it is simpler to sterilise the exterior with a high degree of certainty.
  • ampoules are a safety concern as the tops must be broken off for access to the drug and this may lead to both glass injuries for the staff and the possibility of glass fragments entering the ampoule prior to drug extraction.
  • vials are a preferred option as the plastic or aluminium tops can be safely removed for access to the pharmaceutical via a syringe.
  • a syringe may be used.
  • vials or syringes are significantly more difficult to sterilize than an ampoule as the exterior surface of a vial includes undercuts around the plunger, cap and seal.
  • a steam autoclave may be used to sterilize the exterior surface of a vial containing the pharmaceutical. This may be achieved in a single step.
  • a drawback is that the vial must be steam sterilized for a longer period than normal to allow penetration through an outer packing or container, as well as to the actual vial containing the pharmaceutical.
  • Vials containing heat sensitive pharmaceuticals are not able to be prepared this way.
  • the vials containing the pharmaceuticals are generally aseptically prepared, the vial is examined for low bioburden, and then the vial is placed into an outer container or pack which is then sterilized by ethylene oxide. This is a multi-step procedure. For the above reasons, few pharmaceuticals (especially heat sensitive pharmaceuticals) are provided in theatre pack form unless they are in simple ampoules.
  • the present invention is directed to a method of sterilizing the outer surface of a container containing at least one pharmaceutical which may at least partially overcome at least one of the abovementioned disadvantages or provide the consumer with a safe as well as useful or commercial choice.
  • the present invention in one form, resides broadly in a method of sterilizing the exterior surface of a container.
  • the present invention relates to a method of sterilizing the exterior surface of at least one sealed container, wherein the at least one sealed container each comprise at least one pharmaceutical in fluid form, wherein said method comprises the step of treating the exterior surface of the at least one of sealed container with an alkylene oxide at a concentration of at least 450 mg/L for longer than 350 minutes.
  • the at least one sealed container may be in any suitable form.
  • the at least one sealed container is at least one sealed ampoule, or at least one sealed vial, or at least one sealed syringe, or at least one sealed cartridge; especially at least one sealed vial.
  • the at least one sealed vial may have a detachable lid, tag or cap.
  • the lid may be a screw top lid.
  • the at least one sealed vial may comprise a lower component which contains the pharmaceutical, and an upper component (or lid) which is partially or entirely detachable from the lower component.
  • the upper component may comprise a sealing bung with an enclosure (such as a lid or cap).
  • the lid or a portion of the lid may be peelable or flippable from a lower component.
  • the lower component may be made of any suitable material, such as glass, rubber or plastic.
  • the lower component may comprise a screw thread.
  • the upper component (or lid) may be made of any suitable material, for example glass, rubber or plastic (especially plastic).
  • the upper component (or lid) may comprise an engaging portion for engaging with the screw thread of the lower component to thereby seal the vial.
  • the upper component (or lid) may comprise a rubber bung.
  • the upper component (or lid) may comprise a peelable exterior surface covering the bung.
  • the peelable exterior surface may comprise, for example, aluminium.
  • the at least one sealed syringe may comprise a body, a plunger, and a peelable exterior surface covering the nozzle.
  • the peelable exterior surface may comprise, for example, aluminium, rubber and/or plastic.
  • the sealed container may be suitable for use in hospital emergency rooms and/or operating theatres. Consequently, the exterior surface of the sealed container may be made of any suitable material, such as glass or plastic.
  • the sealed containers may have any suitable volume.
  • the sealed containers (especially sealed vials) have a volume of from 0.1 mL to 100 mL, or from 0.25 mL to 100 mL, or from 0.5 mL to 100 mL, or from 0.5 mL to 50 mL, especially from 0.5 mL to 30 mL, or from 5 mL to 25 mL, or from 0.1 mL to 20 mL, or from 0.5 mL to 20 mL, or from 1 mL to 20 mL, or from 2 mL to 20 mL, or from 0.1 mL to 5 mL, or from 0.25 mL to 5 mL, or from 0.25 mL to 2 mL, or from 0.25 mL to 1 mL, or from 0.1 mL to 2 mL, or from 0.1 mL to 1 mL.
  • the sealed containers (especially vials) may have a volume of 1, 2, 3, 4,
  • the sealed containers each comprise at least one pharmaceutical in fluid form.
  • the fluid may be a liquid or a gel, especially a liquid.
  • the at least one pharmaceutical may be dissolved in the liquid.
  • the at least one pharmaceutical may be suspended in the liquid.
  • the liquid may be transparent, or it may be opaque.
  • the liquid may be syringeable.
  • the liquid may be in the form of a solution, suspension, emulsion or colloid.
  • the liquid may be a lotion.
  • the term “liquid” comprises free-flowing solutions, for example, aqueous solutions (for example a solution which does not comprise a gelation agent).
  • the fluid may have any suitable pH suitable for injection.
  • the fluid has a pH of about 2 to about 9, or about 3 to about 8, or from about 3 to about 5.5, or from about 6.5 to about 8.
  • the fluid is an aqueous liquid.
  • the fluid may be a deoxygenated liquid, especially a deoxygenated aqueous liquid.
  • the fluid may comprise one or more additives.
  • additives may include one or more of an oxygen scavenger (or antioxidant), preservative, or dye (such as an eye dye, including trypan blue and indigocarmine).
  • an oxygen scavenger may be advantageous, for example to assist in minimizing the concentration or amount of oxygen present in the at least one sealed container.
  • the oxygen scavenger may be selected from the group consisting of (but not limited to): ascorbic acid, acetyl cysteine, ethylenediaminetetraacetic acid (EDTA), butylated hydroxytoluene (BHT), thiourea, a sulfite or a combination thereof.
  • the sulfite may be a metabisulfite (especially sodium metabisulfite).
  • any suitable amount of the oxygen scavenger (or antioxidant) may be present in the at least one sealed container.
  • the amount of the oxygen scavenger (or antioxidant) in the composition prepared by the method of the first aspect is from about 0.001 wt% to about 0.50 wt % of the composition, especially from about 0.005 wt% to about 0.35 wt %, or from about 0.01 wt % to about 0.25 wt %, or from about 0.05 wt % to about 0.20 wt %, or about 0.1 wt % of the composition.
  • the at least one pharmaceutical may be at least two pharmaceuticals or at least three pharmaceuticals.
  • the pharmaceutical is one, two, three, four or five pharmaceuticals.
  • the at least one pharmaceutical may be a combination of an analgesic, an anaesthetic, a vasodilator and a vasoconstrictor.
  • the at least one pharmaceutical may include multiple analgesics, multiple anaesthetics, multiple vasodilators, multiple vasoconstrictors, or combinations thereof.
  • the at least one pharmaceutical may be two or more pharmaceuticals of one type, such as lignocaine and tetracaine; or lignocaine and mepivacaine.
  • the at least one pharmaceutical may be adrenaline, lignocaine and tetracaine; it may be adrenaline and lignocaine; it may be adrenaline and bupivacaine; it may be adrenaline and chirocaine; or it may be adrenaline and mepivacaine.
  • At least one of said pharmaceutical may be a sensitive pharmaceutical. At least one of said pharmaceutical may be sensitive to oxygen and/or temperature. For example, at least one said pharmaceutical may degrade in the presence of oxygen. At least one said pharmaceutical may be sensitive to temperature (or significantly degrade at elevated temperatures), such as to a temperature exceeding 10 °C, exceeding 15 °C, exceeding 20 °C, exceeding 25 °C, exceeding 30 °C, exceeding 35 °C, exceeding 40 °C, exceeding 45 °C, exceeding 50 °C, exceeding 55 °C, exceeding 60 °C, exceeding 65 °C, exceeding 70 °C, exceeding 75 °C, exceeding 80 °C, exceeding 85 °C, exceeding 90 °C, exceeding 95 °C or exceeding 100 °C.
  • the at least one pharmaceutical may be at least one selected from the group consisting of: an analgesic, an anaesthetic, a vasodilator and a vasoconstrictor, and combinations thereof.
  • the vasoconstrictor may be selected from the group consisting of: adrenaline, metaraminol, noradrenaline, and clonidine, or combinations thereof.
  • the analgesic may be an opioid analgesic, especially selected from the group consisting of: morphine, fentanyl, alfentanil, remifentanil and sufentanil, or combinations thereof.
  • the anaesthetic may be a local anaesthetic, especially selected from the group consisting of lignocaine (lidocaine), bupivacaine, chirocaine, ropivacaine, procaine, chloroprocaine, tetracaine, oxybupivicaine and mepivacaine, or combinations thereof.
  • the anaesthetic may be selected from the group consisting of: an ester-type anaesthetic, an amide-type anaesthetic, or a combination thereof.
  • Exemplary amide-type anaesthetics include: Articaine, Bupivacaine, Cinchocaine, Etidocaine, Levo-bupivacaine, Lidocaine (lignocaine), Mepivacaine, Oxetacaine, Prilocaine, Ropivacaine, Tolycaine and Trimecaine or a combination thereof.
  • Exemplary ester-type anaesthetics include: Amylocaine, Cocaine, Propanocaine, esters of paraaminobenzoic acid and esters of meta-benzoic acid or a combination thereof.
  • esters of para aminobenzoic acid include: Benzocaine, Butacaine, Butoxycaine, Butyl aminobenzoate, Chloroprocaine, Oxybuprocaine, Parethoxycaine, Procaine, Propoxycaine, Tetracaine and Tricaine, or a combination thereof.
  • esters of meta-benzoic acid include proxymetacaine.
  • the anaesthetic may also be one of the group consisting of: diperodon, dyclonine, ethyl chloride, ketocaine, myrtecaine, octacaine, pramocaine, propipocaine and quinisocaine or a combination thereof.
  • the anaesthetic may also be a combination of the aforementioned anaesthetics, and may include D and L forms of the aforementioned anaesthetics (if they exist).
  • the at least one pharmaceutical may comprise at least one sensitive pharmaceutical and at least one non-sensitive or further pharmaceutical.
  • the at least one pharmaceutical may comprise non-sensitive pharmaceuticals.
  • sensitive pharmaceuticals include metaraminol, catecholamines (including adrenaline, noradrenaline, isoprenaline, dopamine and dobutamine), opioids (including morphine, fentanyl, sufentanyl), and clonidine.
  • the at least one pharmaceutical may be at least one selected from the group consisting of: metaraminol, a catecholamine, an opioid, and clonidine, or a combination thereof.
  • the catecholamine may be selected from the group consisting of: adrenaline, noradrenaline, isoprenaline, dopamine and dobutamine, or a combination thereof. Chemically, the catechol substructure of such catecholamines appear to be primarily responsible for the propensity to oxidize of these pharmaceuticals.
  • the opioid may be selected from the group consisting of (but not limited to): morphine, codeine, pethidine, fentanyl, alfentanil, remifentanil and sufentanil, or a combination thereof.
  • adrenaline may have some stability if stored at lower temperatures, dramatic decreases in the concentration of adrenaline may be observed if compositions are stored at higher temperatures. For example, it was found that adrenaline can be stable for at least 28 days under both acidic and basic conditions when stored in a freezer, but at higher temperatures (4 °C and above) concentration loss of 100% was observed after 2 days, or within 90 minutes at 22 °C (Palazzolo et al).
  • the at least one pharmaceutical may be present in the fluid at any suitable concentration.
  • the at least one or each pharmaceutical may be at a concentration of from 0.01% to 10%, or from 0.05% to 5% (w/v).
  • the anesthetic such as lignocaine or bupivacaine
  • the vasoconstrictor such as adrenaline
  • the vasoconstrictor may be at a concentration of from 1:100,000 to 1:500,000, or from 1:200,000 to 1:400,000.
  • the at least one sealed container may comprise a gaseous headspace.
  • the gas in the headspace may comprise less than 10% oxygen (by volume), especially less than 7.5% oxygen, or less than 5% oxygen, or less than 4.5%, less than 4%, less than 3.5%, less than 3%, less than 2.5%, less than 2%, less than 1.5%, less than 1%, less than 0.75%, less than 0.50%, or less than 0.25% oxygen.
  • the gas in the headspace may comprise an inert gas.
  • exemplary inert gases may include nitrogen, or a noble gas.
  • the noble gas may be selected from the group consisting of helium, neon, argon, krypton, xenon and radon; especially helium, neon or argon; more especially argon.
  • the inert gas is nitrogen or argon; especially nitrogen.
  • the gas in the headspace may comprise at least 50% inert gas (by volume), especially at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, or at least 99% inert gas.
  • the at least one sealed container may be any number of sealed containers.
  • the at least one sealed container may be at least two sealed containers, or a plurality of sealed containers.
  • the at least one sealed container is at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at least 95 or at least 100 sealed containers, especially at least 20 sealed containers, more especially 30 sealed containers, or more than 50 sealed containers, or more than 60 sealed containers.
  • the at least one sealed container is at least 100, at least 200, at least 300, at least 400, at least 500, at least 800, at least 1000, at least 1500, at least 2000, at least 2500, at least 3000, at least 3500 or at least 4000 sealed containers.
  • the method may comprise applying an outer casing to each at least one sealed container.
  • At least one (especially each one) sealed container may comprise an outer casing.
  • the outer casing may be a wrap.
  • the outer casing may be formed of any suitable material.
  • the outer casing may be or comprise a plastic.
  • the outer casing may comprise at least one layer, especially an inner layer and an outer layer.
  • the inner layer may be or comprise a polyalkylene.
  • the polyalkylene may be polypropylene (PP) or polyethylene terephthalate glycol (PETG).
  • PETG polyethylene terephthalate glycol
  • the inner layer may especially be PETG. PETG has an advantage over PP as it is more transparent and allows the inner vial label to be read.
  • the outer layer may comprise or be a polymer.
  • the polymer may comprise fibers.
  • the polymer may be a poly alkylene polymer.
  • the polymer may comprise poly alkylene fibers.
  • the polyalkylene may be polyethylene.
  • the polymer may comprise polyethylene fibers.
  • the polymer may comprise spunbound polyethylene fibers.
  • a polymer comprising a layer of spunbound polyethylene fibers is Tyvek®.
  • the wrap may be water-resistant.
  • the wrap may be durable.
  • the wrap may be printable.
  • the wrap may allow for the alkylene oxide to penetrate and exit (or ingress and egress).
  • Tyvek® is durable, water-resistant, printable and allows ethylene oxide penetration and egress following the method.
  • the method of the first aspect comprises:
  • the step of initially sterilizing the exterior surface of the at least one sealed container may comprise heat or aseptic sterilization.
  • a step of heat sterilization may comprise using an autoclave. However, in some embodiments there may be no initial sterilization step.
  • each at least one sealed container is labelled.
  • each at least one sealed container is inspected for defects.
  • the method comprises the step of placing each at least one sealed container into a pack, especially wherein the at least one sealed container comprises an outer casing. Consequently, after step (ii) the method may comprise the step of placing the at least one sealed container into a pack.
  • the method of the first aspect is a method of sterilizing at least one pack, wherein each said pack comprises at least one sealed container (especially wherein each of the at least one sealed container comprises an outer casing).
  • the at least one pack may be at least two packs, or a plurality of packs.
  • One factor in the design of the sterilisation parameters is that after sterilisation and a vacuum removal of the alkylene oxide residues, that the seal remains intact and so unusual or extended stress is a factor in the development of a sterilisation procedure.
  • a further factor is the bioburden load on the vial once it is sterilised, wrapped by the wrap, labelled and serialised, and prior to insertion into the pack.
  • the bioburden can be maintained below a level of less than 50CFU per device (especially with a PETG/Tyvek® pack) however as the biological indicators added to any load contain over 10 6 spores per unit provided that the sterilised vials are kept in clean storage the external vial bioburden is a low issue.
  • Each pack may comprise at least one container, or at least 2 containers, especially at least 3 or at least 4 or at least 5 containers.
  • Each pack may comprise less than 20 containers, especially less than 15 containers, or less than 10 containers. In one embodiment, each pack comprises 5 containers.
  • the at least one, or a plurality of packs may be present in a box or carton. Consequently, in one embodiment, the method of the first aspect is a method of gaseous sterilizing a box or carton, or a plurality of boxes or cartons (or at least two boxes or cartons), wherein each said box or carton comprises at least one of pack which each comprise at least one sealed container. In another embodiment, the method of the first aspect is a method of sterilizing a box or carton, or a plurality of boxes or cartons, wherein each said box or carton comprises a plurality of the sealed containers.
  • the box or carton may be made of any suitable material, for example a cellulosic material, especially cardboard.
  • the box or carton may comprise an upper portion and a lower portion.
  • the box or carton may form a cube or a rectangular prism.
  • the lower portion may have a base and four side walls which extend from the base.
  • the four side walls may comprise two pairs of opposed side walls.
  • the upper portion may be a lid.
  • the upper portion may be removable from the lower portion.
  • the upper portion may be connected to the lower portion, for example via a hinge along one side wall.
  • the box or carton may be a shipper.
  • each box or carton may comprise any number of packs.
  • each box or carton comprises from 5 to 30 packs, especially from 10 to 20 packs, or from 15 to 20 packs, or 16 packs.
  • each box or carton comprises from 40 to 150 sealed containers, especially from 40 to 120 sealed containers, more especially from 50 to 110 sealed containers, or from 60 to 100 sealed containers, or from 70 to 90 sealed containers, or about 80 sealed containers.
  • Each box or carton may have any suitable height, width and length.
  • each box or carton has a height of from 50 mm to 500 mm, especially from 50 mm to 400 mm, or from 100 mm to 350 mm, or from 150 mm to 300 mm, or from 200 mm to 250 mm or from 210 mm to 230 mm or about 218 mm.
  • each box or carton has a length of from 200 mm to 700 mm, especially from 250 mm to 500 mm, or from 300 mm to 450 mm or from 350 mm to 400 mm or about 375 mm.
  • each box or carton has a depth of from 50 mm to 500 mm, especially from 100 mm to 400 mm, or from 150 mm to 350 mm, or from 200 mm to 300 mm, or from 230 mm to 280 mm or from 240 mm to 270 mm or about 256 mm. In one embodiment, each box or carton is 375 mm x 256 mm x 218 mm.
  • the plurality of boxes or cartons may provide a pallet. Consequently, in one embodiment, the method of the first aspect is a method of sterilizing a pallet or a plurality of pallets, wherein each said pallet comprises a plurality of the sealed containers. In another embodiment, the method of the first aspect is a method of sterilizing a pallet or a plurality of pallets, wherein each said pallet comprises a plurality of boxes or cartons, wherein each said box or carton comprises a plurality of the sealed containers.
  • the method of the first aspect is a method of sterilizing a pallet or a plurality of pallets, wherein each said pallet comprises a plurality of boxes or cartons, wherein each said box or carton comprises a plurality of packs, wherein each pack comprises a plurality of the sealed containers.
  • each box or carton comprises at least a first side and at least a second side; wherein the at least a first side of each box or carton is entirely unobstructed in the pallet, and at least a second side of each box or carton is at least partially unobstructed in the pallet.
  • at least one face of each box or carton is unobstructed in the pallet.
  • each box or carton is unobstructed in the pallet, and at least a second face of each box or carton is at least partially unobstructed in the pallet. If the box or carton is a cube or rectangular prism then each said box or carton has six faces.
  • each box or carton is unobstructed in the pallet (or exposed surface area), especially from 12% to 80%, or from 12 % to 70% of the surface area of each box or carton is unobstructed in the pallet (or exposed surface area).
  • at least 10% of the surface area of each box or carton is unobstructed in the pallet (or exposed surface area), especially at least 12% of the surface area of each box or carton is unobstructed in the pallet (or exposed surface area), more especially at least 13%, 14% or 15% of the surface area of each box or carton is unobstructed in the pallet (or exposed surface area).
  • At least 20% of the surface area of each box or carton is unobstructed in the pallet (or exposed surface area), especially at least 25% of the surface area of each box or carton is unobstructed in the pallet (or exposed surface area), more especially at least 30%, 32% or 34% of the surface area of each box or carton is unobstructed in the pallet (or exposed surface area). It was found that if the exposed surface area of each box or carton on the pallet was too low, then this may decrease the effectiveness of the sterilisation procedure. This packing arrangement is not consistent with standard pallet packing arrangements, where the maximum number of boxes or cartons are typically placed in a given volume.
  • unobstructed means that said face or side is not abutting another box or container. An unobstructed face or side is therefore exposed to surrounding gases.
  • the pallet may be of any suitable dimensions.
  • the pallet has dimensions of from 500 mm to 2000 mm in width or length, especially from 800 mm to 1500 mm in width or length, most especially from 1000 mm to 1400 mm in width or length, or about 1165mm in width and/or length.
  • the pallet may be of any suitable height.
  • the height of the boxes or cartons on the pallet is less than 800 mm, especially less than 650 mm or less than 600 mm.
  • the height of the boxes or cartons on the pallet is 594 mm.
  • the inventors have advantageously found that when there are no more than 2 rows of boxes or cartons on the pallet or when the height of the boxes or cartons on the pallet is less than 600 mm, then the alkylene oxide is better able to permeate the boxes and cartons and sterilise the at least one container (or the plurality of containers).
  • the total volume of the pallet is less than 1.2 m 3 , especially less than 1.1 m 3 , or less than 1 m 3 , or less than 0.9 m 3 . In one embodiment, the total volume of the pallet is about 0.8 m 3 .
  • the total weight of the pallet may be from 100 to 200 kg, especially from 120 to 160 kg, or 130 to 150 kg or about 141.5 kg (excluding the pallet frame itself, such as a wooden pallet frame). Including the pallet frame, the total weight of the pallet may be from 120 to 220 kg, especially from 140 to 200 kg, or 150 to 190 kg, or 165 to 175 kg or about 171.5 kg.
  • the total density of the pallet may be from 100 to 300 kg/m 3 , especially from 160 to 260 kg/m 3 , or from 180 to 240 kg/m 3 , or from 205 to 225 kg/m 3 , or about 212.8 kg/m 3 .
  • the total density of the pallet may be less than 300 kg/m 3 , especially less than 250 kg/m 3 .
  • the pallet may have less than 35 boxes or cartons, especially less than 30 boxes or cartons, or less than 26 boxes or cartons.
  • the pallet may have from 10 to 35 boxes or cartons, or from 20 to 30 boxes or cartons, or from 23 to 28 boxes or cartons, or from 25 to 27 boxes or cartons, or about 26 boxes or cartons.
  • More than one pallet may be sterilised at any one time.
  • 1, 2, 3 or 4 pallets may be treated with the alkylene oxide at one time.
  • the pallet(s) (or the at least one sealed container) occupy less than 60%, less than 50%, less than 40% or less than 30% of the sterilization chamber volume.
  • the pallet does not include an outer wrap to hold the boxes or cartons in place.
  • the pallet does not include a polyvinyl chloride (PVC) outer wrap.
  • PVC polyvinyl chloride
  • the inventors have found that use of a PVC outer wrap may impede alkylene oxide penetration.
  • an outer wrap that is permeable to an alkylene oxide may be used.
  • the step of treating the exterior surface of the at least one sealed container is a step of sterilizing the exterior surface of the at least one sealed container.
  • the term “sterilized” or “sterilizing” does not mean that the exterior surface is completely sterile, however the exterior surface must be sufficiently sterile for use in emergency departments and operating rooms.
  • the exterior surface of the container is sterilized if it has fewer than 100 CFU per container, especially less than 75 CFU per container, or less than 50 CFU per container.
  • the alkylene oxide may be a C2-C6 alkylene oxide, especially ethylene oxide, propylene oxide or butylene oxide, most especially ethylene oxide.
  • the concentration of the alkylene oxide may be greater than 500 mg/L.
  • the concentration of the alkylene oxide may be no more than 1000 mg/L.
  • the concentration of the alkylene oxide may be from 500 to 850 mg/L, especially from 550 to 800 mg/L or from 600 to 800 mg/L. This is higher than a typical ethylene oxide sterilisation.
  • the treatment (exposure time) with the alkylene oxide may be greater than 400 minutes, especially greater than 430 minutes, or greater than 440 minutes, or greater than 450 minutes, or greater than 460 minutes or greater than 470 minutes, or greater than 480 minutes.
  • the treatment (exposure time) with the alkylene oxide may be less than 800 minutes, especially less than 700 minutes, or less than 650 minutes, or less than 600 minutes, or less than 550 minutes, or less than 500 minutes.
  • the treatment (exposure time) with the alkylene oxide may be from 400 minutes to 800 minutes, especially from 420 minutes to 650 minutes, or from 430 to 550 minutes, or from 440 to 500 minutes.
  • the treatment (exposure time) with the alkylene oxide may about 480 to 485 minutes. This is significantly longer than a typical ethylene oxide sterilisation which is typically about 180 minutes.
  • the inventors found that the longer sterilisation time was critical to enable the alkylene oxide to pass throughout the load and provide even penetration.
  • the mass of alkylene oxide used in the chamber may be from 30 kg to 40 kg, especially from 32 to 38 kg, or from 35 to 36 kg.
  • the chamber temperature in the treatment step may be from 40 to 70 °C, especially from 45 to 65 °C, or from 50 to 65 °C, or from 50 to 60 °C, or from 55 to 65 °C, or from 55 to 63 °C.
  • the chamber humidity in the treatment step may be from 35 to 100 %, especially from 35 to 90% or from 35 to 85%.
  • the chamber pressure may be from 40 kPa to 75 kPa, especially from 42 kPa to 73 kPa, more especially from 45 kPa to 70 kPa.
  • the method may include a step of preconditioning the at least one container before the treatment with the alkylene oxide.
  • the preconditioning step may be a step of acclimating the at least one container to the temperature and humidity used for the treatment step.
  • the preconditioning step may be performed for more than 5 hours, especially more than 6 hours, or more than 7, 8, 9, 10, 11 or 12 hours.
  • the preconditioning step may be performed at a temperature of from 40 to 70 °C, especially from 45 to 65 °C, or from 50 to 60 °C.
  • the preconditioning step may be performed at a humidity of from 35 to 100 %, especially from 35 to 90% or from 35 to 85%.
  • the preconditioning step may have a transfer time of less than 1.5 hours, especially less than 1.2 hours or less than 1 hour.
  • the method may include a step of aeration after the step of treatment with the alkylene oxide.
  • the aeration step may be performed for at least 8 hours, especially at least 9 hours, or at least 10 hours.
  • the aeration step may be performed at a temperature of from 40 to 70 °C, especially from 45 to 65 °C, or from 45 to 60 °C, or from 50 to 60 °C, or 45 to 55 °C, or about 50 °C.
  • the present invention relates to at least one sealed container sterilized by the method of the first aspect.
  • transitional phrase “consisting essentially of” is used to define a composition, process or method that includes materials, steps, features, components, or elements, in addition to those literally disclosed, provided that these additional materials, steps, features, components, or elements do not materially affect the basic and novel characteristic(s) of the claimed invention.
  • the term “consisting essentially of” occupies a middle ground between “comprising” and “consisting of”.
  • Figure 1 provides a perspective view of a pallet of boxes or cartons for sterilization, wherein each box or carton comprises a plurality of containers, in which the pallet comprises two rows of boxes or cartons;
  • Figure 2 provides a perspective view of a pallet of boxes or cartons for sterilization, wherein each box or carton comprises a plurality of containers, in which the pallet comprises one row of boxes or cartons;
  • Figure 3 provides a top view of the pallet of Figure 1 or Figure 2;
  • Figure 4 provides a perspective view of a box or carton used in Figure 1 or Figure 2.
  • the below Examples relate to containers in which the pharmaceutical is a combination of adrenaline and bupivacaine, or adrenaline and lidocaine (lignocaine).
  • Adrenaline is sensitive to the presence of oxygen and heat, and consequently the concentration of adrenaline in the container may be affected by these factors.
  • the pharmaceutical is present in an aqueous solution at a pH of from about 3.0 to 5.5.
  • Containers were used, in the form of vials (20 mF) with typical rubber bung seals held in place by flip top aluminium closures.
  • the pharmaceutical composition of the interior of the containers comprised the adrenaline and bupivacaine aqueous solution, or the adrenaline and lidocaine aqueous solution.
  • the vials were all inspected for faults, including glass fractures, particulates or other unacceptable cosmetic damage or contamination.
  • Vials were then labelled and serialized (if required) and individual vials were prepared by wrapping each vial in an outer casing.
  • the outer casing comprised two layers, with the inner layer being polyethylene terephthalate glycol (PETG) or polypropylene (PP). It was found that use of PETG was advantageous as it was more transparent and it allowed the vial label to be read.
  • the outer layer was a Tyvek® sheet. Tyvek® is a polymer comprising a layer of spunbound polyethylene fibers.
  • each box or carton has a height of 218 mm, a width of 256 mm and a length of 375 mm.
  • the box comprises a lower portion (having a base and four side walls) and an upper portion which is a lid hinged along one sidewall of the lower portion.
  • An exemplary box or carton 10 is illustrated in Figures 1- 4. Each box or carton weighed about 5.45 kg.
  • FIG. 1 Many of the boxes or cartons were then placed on a pallet 20.
  • the pallet 20 was 1.165m wide and 1.165 m long. 13 boxes or cartons may be placed on each pallet (as shown in Figure 2) or 26 boxes or cartons (as shown in Figure 1).
  • a comer box or carton has about 50% of the surface area of the box or carton unobstructed (and exposed to the alkylene oxide during sterilization - this does not include exposed area on the underside of the box or carton, where the box or carton abuts the pallet).
  • the centermost box or carton has an exposed surface area of about 55% (not counting the exposed area on the underside of the box or carton, where the box or carton abuts the pallet). However, some of the middle boxes or cartons along the side of the pallet would have an exposed surface area of from about 36% to about 44% (not counting the exposed area on the underside of the box or carton, where the box or carton abuts the pallet).
  • each total weight of the pallet illustrated in Figure 1 was 141.5 kg for the boxes or cartons, and the wood pallet frame weighed 30 kg, making the total weight of the pallet 171.5kg.
  • the total volume of the pallet illustrated in Figure 1 was 0.806 cubic metres. Therefore, the density of the pallet was 212.8 kg/m 3 .
  • a plastic wrap such as a PVC plastic wrap is used around the outside of a pallet to hold the boxes or cartons in place (this is especially important on a high stacked pallet).
  • a plastic wrap was not used on the pallet as it was found that this wrap impeded gas penetration.
  • the preconditioning time above is longer than a standard procedure (which is typically about 10 hours).
  • the mass of ethylene oxide above is significantly higher (in a typical cycle the mass would be about 25 to 26 kg, but the inventors found that this was insufficient for complete sterility).
  • the exposure time was also significantly longer (in a standard cycle the exposure time is typically 180-185 minutes. This is an increase of nearly 400% and the inventors found that this was necessary to obtain adequate gas penetration).
  • the pressure was also significantly higher above (a typical pressure would be about 30 kPa to 55 kPa).
  • the packing arrangement (as illustrated in the Figures) was also found to be important to enable the ethylene oxide to permeate the boxes and cartons and sterilize a plurality of containers, and further at the end to allow degassing and removal of all residual ethylene oxide.
  • the typical ethylene oxide sterilization chamber pallet load of three pallets needed to have the load more spaced (or reduced) out to fit over 6 pallets (i.e. a doubling of the space requirement).
  • the total load was either 3.22 m 3 (4 pallets) to 4.8 m 3 (6 pallets).
  • Results illustrating the stability and sterilization of vials produced according to the above procedures are shown in Tables 3-12.
  • the formulations shown in Tables 3, 5, 7, 10 and 11 are stable for at least 12 months at 25 °C / 60% RH (at least 18 months for Tables 7 and 10; and at least 24 months for Table 11).
  • the formulations shown in Tables 4, 6, 8, 9 and 12 are stable for at least 6 months at 40 °C / 75% RH.
  • Table 8 Containers in which the pharmaceutical is Lidocaine HC12.0% with Adrenaline 1:200,000 Injection 20mL in 20mL Theatre Pack
  • Table 9 Containers - Pharmaceutical is Bupivacaine hydrochloride 0.25% with Adrenaline 1:400,000 Injection 20mL in 20mL Theatre Pack
  • Table 11 Containers - Pharmaceutical is Bupivacaine hydrochloride 0.5% with Adrenaline 1:200,000 Injection 20mL in 20mL Theatre Pack
  • Table 12 - Containers - Pharmaceutical is Bupivacaine hydrochloride 0.5% with Adrenaline 1:200,000 Injection 20mL in 20mL Theatre Pack
  • a method of sterilizing at least one sealed container according to one embodiment of the method of the first aspect of the invention may have advantages such as:

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mechanical Engineering (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)

Abstract

La présente invention concerne, entre autres, un procédé de stérilisation de la surface extérieure d'au moins un contenant scellé et une pluralité de contenants scellés stérilisés selon le procédé. Dans le procédé, le ou les contenants scellés comprennent chacun au moins un produit pharmaceutique sous forme fluide, et le procédé comprend l'étape de traitement de la surface extérieure du ou des contenants scellés avec un oxyde d'alkylène à une concentration d'au moins 450 mg/L pendant plus de 350 minutes.
PCT/AU2024/050280 2023-03-27 2024-03-27 Procédé de stérilisation Pending WO2024197344A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024254746A AU2024254746A1 (en) 2023-03-27 2024-03-27 Method of sterilisation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2023900854A AU2023900854A0 (en) 2023-03-27 Method of sterilisation
AU2023900854 2023-03-27

Publications (1)

Publication Number Publication Date
WO2024197344A1 true WO2024197344A1 (fr) 2024-10-03

Family

ID=92902873

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2024/050280 Pending WO2024197344A1 (fr) 2023-03-27 2024-03-27 Procédé de stérilisation

Country Status (2)

Country Link
AU (1) AU2024254746A1 (fr)
WO (1) WO2024197344A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008077155A1 (fr) * 2006-12-21 2008-06-26 Genentech, Inc. Stérilisation d'objets contenant des molécules biologiques
US20170349313A1 (en) * 2016-06-01 2017-12-07 Centurion Medical Products Corporation Methods for manufacturing non-glass prefilled syringes
US20180333374A1 (en) * 2017-05-16 2018-11-22 Jugal K. Taneja More potent and less toxic formulations of epinephrine and methods of medical use
WO2018215580A1 (fr) * 2017-05-24 2018-11-29 Formycon Ag Procédé de stérilisation de seringues en plastique pré-remplies contenant un antagoniste du vegf
US20200171244A1 (en) * 2017-05-24 2020-06-04 Sio2 Medical Products, Inc. Sterilizable pharmaceutical package for ophthalmic formulations
US20200282130A1 (en) * 2017-09-29 2020-09-10 F. Hoffmann-La Roche Ag Prefilled syringe and method of preparing a prefilled syringe

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008077155A1 (fr) * 2006-12-21 2008-06-26 Genentech, Inc. Stérilisation d'objets contenant des molécules biologiques
US20170349313A1 (en) * 2016-06-01 2017-12-07 Centurion Medical Products Corporation Methods for manufacturing non-glass prefilled syringes
US20180333374A1 (en) * 2017-05-16 2018-11-22 Jugal K. Taneja More potent and less toxic formulations of epinephrine and methods of medical use
WO2018215580A1 (fr) * 2017-05-24 2018-11-29 Formycon Ag Procédé de stérilisation de seringues en plastique pré-remplies contenant un antagoniste du vegf
US20200171244A1 (en) * 2017-05-24 2020-06-04 Sio2 Medical Products, Inc. Sterilizable pharmaceutical package for ophthalmic formulations
US20200282130A1 (en) * 2017-09-29 2020-09-10 F. Hoffmann-La Roche Ag Prefilled syringe and method of preparing a prefilled syringe

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "A Comparison of Gamma, E-beam, X-ray and Ethylene Oxide Technologies for the Industrial Sterilization of Medical Devices and Healthcare Products - White Paper", 31 August 2017 (2017-08-31), XP093219189, Retrieved from the Internet <URL:http://large.stanford.edu/courses/2018/ph241/goronzy2/docs/gipa-aug17.pdf> *
DANIEL LANZON: "Qualification of Ethylene Oxide and Gamma Sterilisation Processes", PDA PRESENTATION - PFIZER PERTH, PARENTERAL DRUG ASSOCIATION, AUSTRALIA, Australia, pages 1 - 36, XP009560209, Retrieved from the Internet <URL:https://web.archive.org/web/20221205210031/https://www.pda.org/docs/default-source/website-document-library/chapters/presentations/australia/ethylene-oxide-gamma-sterilisation-trials-and-tribulations-18-september-2012-presentation-two.pdf?sfvrsn=9f1ba08e_6> [retrieved on 20240514] *

Also Published As

Publication number Publication date
AU2024254746A1 (en) 2025-10-02

Similar Documents

Publication Publication Date Title
US9908682B2 (en) Storage of ampoules containing pharmaceutical formulations using a sealed container comprising an oxygen scavenger
US10806850B2 (en) Medical apparatus and method for sterilizing medical apparatus
ES2258675T3 (es) Proceso para la fabricacion de un empaque comprimible esteril para un producto farmaceutico.
EP1349580B2 (fr) Procede permettant d&#39;ameliorer la stabilite d&#39;une composition pharmaceutique
US20200289439A1 (en) Process of Manufacturing a Stable, Ready To Use Infusion Bag For An Oxidation Sensitive Formulation
JP7514844B2 (ja) 単回用量包装クロトリマゾール液体組成物
AU2024254746A1 (en) Method of sterilisation
PT1786680E (pt) Frasco protegido, e método para fabricar o mesmo
JP4307911B2 (ja) エアゾール容器、エアゾール製品、およびこれらの製造方法
US20030203044A1 (en) Wound-treating gel
JP2024517732A (ja) 低密度ポリエチレンのコンテナに含まれるデクスメデトミジンの溶液
HK40063022A (en) Single-dose packaged clotrimazole liquid composition
HK40063022B (en) Single-dose packaged clotrimazole liquid composition
Plunger et al. Anatomy of the Zeyco dental cartridge: A guide for healthcare professionals
JPH0256896B2 (fr)
Dam Sore Recent Advances in the Packaglng of Pharmceuticals (II)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24777319

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: AU2024254746

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 825698

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2024254746

Country of ref document: AU

Date of ref document: 20240327

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 825698

Country of ref document: NZ